Study of Xeloda and Gleevec in Patients With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 31, 2002

Primary Completion Date

July 31, 2009

Study Completion Date

August 31, 2010

Conditions
Colon CancerColorectal Cancer
Interventions
DRUG

capecitabine, imatinib mesylate

Capecitabine and imatinib mesylate will both be taken by mouth twice a day

Trial Locations (1)

90033

USC/Norris Cancer Center, Los Angeles

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

University of Southern California

OTHER

NCT00183833 - Study of Xeloda and Gleevec in Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter